Scarey isnt it!
And considering that oncology treatments will be needeed regardless of the surrounding economic situation. Looks like we have a brief opportunity to accumulate before final results come in. EG Capital has a new price target of $1.80.
AVX may also be one to keep an eye on in the area of HIV. Another resistance story in a chronic life long treatment area.
Add to My Watchlist
What is My Watchlist?